Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 67

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 67
---
 Kadimastem will continuously monitor its compliance with such criteria as they evolve from time to time. Q.Will shareholders be informed whether the combined company has received Nasdaq listing approval prior to the shareholder vote on the Merger and related proposals? Yes. To the extent such approval is not obtained before this proxy statement/prospectus is finalized, NLS will furnish a Report on Form 6 -Kto disclose such approval. ix Q.How does the NLS Board recommend NLS shareholders vote? After careful consideration, the NLS Board recommends that NLS’s shareholders vote: •“FOR” Proposal No. 1 to approve the Merger Agreement. •“FOR” Proposal No. 2 to approve the par value reduction, the reverse split and the ordinary share capital increase with contribution of the Kadimastem shares to implement the Merger. •“FOR” Proposal No. 3 to approve the ordinary share capital increase regarding the issuance of preferred shares. •“FOR” Proposal No. 4 to approve the reinstatement of the capital band. •“FOR” Proposal No. 5 to approve the conditional share capital for employee and advisory options. •“FOR” Proposal No. 6 to approve the conditional share capital for shareholders’ options. •“FOR” Proposal No. 7 to approve the transfer and voting rights limitation of 9.99%. •“FOR” Proposal No. 8 to approve the name change of NLS. •“FOR” Proposal No. 9 to approve the election of the new members to the NLS Board. •“FOR” Proposal No. 10 to approve the election of members of the Compensation, Nomination and Governance Committee. •“FOR” Proposal No. 11 to approve the composition of the new senior management following the Merger. •“FOR” Proposal No. 12.1 to approve the compensation for the members of the NLS Board. •“FOR” Proposal No. 12.2 to approve the compensation for the executive officers. •“FOR” Proposal No. 13 to approve the CVR Agreement. •“FOR” Proposal No. 14 to approve the conversion of outstanding options and RSUs issued by Kadimastem. Q.What will happen in the Merger? At the Effective Time, each: •Kadimastem Ordinary Share issued and outstanding immediately prior to the Effective Time will be exchanged for the right to receive a number of newly issued, fully paid and nonassessable NLS Common Shares equal